Disclosed herein is a method and system for detecting exposure of a patient to an infectious pathogen, as well as customized treatment of an infected patient by analysis and classification of the patient's microbiome. The methodology described herein provides detection, analysis, and treatment of a subject exposed to an infectious pathogen.

The present document describes a dual-affinity probe comprising an inorganic surface binding peptide and a target-specific capture element, which may bind to various targets, such as pathogens. This document further describes uses of the dual-affinity probe, e.g., to determine the presence of and/or quantity of a target in a sample. In particular embodiments, the dual-affinity probe is specific for SARS-CoV-2 (Spike or Nucleocapsid) protein and may be used to determine whether a subject is infected with SARS-CoV-2.

The present disclosure provides a biosensor for the detection of protease activity. The detection of protease activity can be used for the detection of viral infection, in particular coronavirus infection. The biosensor described herein can be used to detect SARS-CoV-2. The present disclosure also provides vectors expressing the biosensor and methods for using the same.

The disclosure is directed to methods and apparatus for the detecting, diagnosis of infection with SARS-CoV-2. The disclosure includes methods for detecting a current or former SARS-CoV-2 infection in an animal, methods for diagnosing and treating an animal infected with SARS-CoV-2. in various aspects, the disclosure is directed to the detection of a nucleocapsid polypeptide of SARS-CoV-2 in a sample from an animal, the detection of a portion of a spike polypeptide of SARS-CoV-2 in a sample from and animal, or detection of both a portion of a spike polypeptide of SARS-CoV-2 and a portion of a nucleocapsid polypeptide of SARS-CoV-2 in a sample from an animal.

An object of the present invention is to provide a SARS-CoV-2 detection kit and a SARS-CoV-2 detection method which make it possible to simply detect SARS-CoV-2 with higher sensitivity. According to the present invention, there is provided a SARS-CoV-2 detection kit which is for specifically detecting a nucleocapsid protein contained in a biological specimen and contains at least one antibody that specifically reacts with a SARS-CoV-2 nucleocapsid protein (NP), the SARS-CoV-2 detection kit including a first container that houses a silver-containing compound, and a second container that houses a reducing agent capable of reducing silver ions, in which the antibody includes at least one antibody that belongs to a subclass IgG2b.

A spring element is provided for analysis of the presence of an analyte in a sample. The spring element includes a flexible main body having a conductivity detector zone and a binding zone. The conductivity of the conductivity detector zone is determined by electronic tunneling, ionization or hopping processes, and the conductivity detector zone is formed from nanoparticles embedded in a matrix that have higher electrical conductivity compared to the matrix material. Moreover, the binding zone includes at least one binding molecule that binds to the analyte and is coupled to the main body.

The present invention provides a device for detecting an analyte in a sample, including a chamber for receiving a testing element, where the testing element has a first position and a second position in the chamber; the testing element is not in contact with a fluid sample when the testing element is located in the first position, and the testing element is in contact with a fluid sample when the testing element is located in the second position.

The instant disclosure discloses an antibody or antigen-binding fragment thereof binding to Porcine Reproductive and Respiratory Syndrome Virus (PRRSV), and uses of such antibody or antigen-binding fragment thereof to create immunoassay methods or devices for PRRSV detection.

Provided herein are methods of detecting an antibody directed against a pathogen and uses thereof.

A nanobody and its application based on SARS-CoV-2 S protein are provided, and the present disclosure relates to biomedical technology. The present disclosure chooses the Spike S1+S2 ECD of SARS-CoV-2 as a target, and screens the nanobody against of SARS-CoV-2 by using a nanobody library. After an ELISA test, the Spike S1+S2 ECD target of SARS-CoV-2 can be specifically identified while a SPIKE RBD target is identified, and a binding signal is relatively strong. The corresponding nanobody sequence is constructed into a prokaryotic expression vector for expression and purification to express the target nanobody successfully. After the purification, the purity is greater than 90%. The ELISA test of VHH nanobody showed that the purified nanobody has higher affinity to the two targets.